- Symbiosis Pharmaceutical Services has installed a 30°C stability chamber to expand its QC laboratory capabilities.
- The addition enables full replication of all ICH-defined climatic zones, supporting global drug product stability testing.
Symbiosis Pharmaceutical Services has expanded its Quality Control (QC) laboratory with the installation of a new 30°C stability chamber, enhancing its contract manufacturing and analytical capabilities for injectable drug products. The upgrade enables the company to replicate all four ICH-defined climatic zones for stability testing.
The addition allows Symbiosis to assess drug product performance under a full range of global storage conditions. This supports pharmaceutical and biotechnology partners in preparing products for worldwide distribution by aligning with ICH Q1A(R2) guidelines.
The QC laboratory, commissioned in 2023 and operational since 2024, plays a central role in supporting client programs. It enables faster data turnaround, improves operational efficiency, and provides a streamlined path from development through manufacturing to release.
The new chamber complements existing stability capabilities at –80°C, –20°C, 5°C, 25°C, and 40°C. Together, these conditions complete the full suite required for global climatic zone coverage in sterile injectable drug product testing.
“The addition of our new 30°C stability storage capability marks another important stage in the expansion of Symbiosis commercial drug product supply services.”
Joanne Anderson, Chief Commercial Officer at Symbiosis
